Skip to main content

Table 3 Patients' characteristics according to ICIs initiation within 3 months of death

From: PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

  Control ICIs started within 3 months of death  
N° (%) N° (%)
444 (78.3) 123 (21.7)
Age    
 < 60 years old 124 (27.9) 24 (19.5) P = 0.0603
P = 0.8261
 ≥ 60 years old 320 (72.1) 99 (80.5)
 < 70 years old 254 (57.2) 69 (56.1)
 ≥ 70 years old 190 (42.8) 54 (43.9)
Gender    P = 0.3171
 Female 155 (34.9) 37 (30.1)
 Male 289 (65.1) 86 (69.9)
ECOG PS    P < 0.0001
 0—1 387 (87.2) 87 (70.7)
  ≥ 2 57 (12.8) 36 (29.3)
Primary tumor    P = 0.0236
 NSCLC 261 (58.8) 91 (74.0)
 Melanoma 94 (21.2) 17 (13.8)
 Renal cell carcinoma 71 (16.0) 12 (9.8)
 Others 18 (4.1) 3 (2.4)
No. of metastatic sites    P = 0.0025
 ≤ 2 182 (41.0) 32 (26.0)
  > 2 262 (59.0) 91 (74.0)
Treatment line    P = 0.0189
 First 138 (31.1) 35 (28.5)
 Second 243 (54.7) 81 (65.9)
 Further lines 63 (14.2) 7 (5.7)
  1. ICI: immune checkpoint inhibitor; ECOG-PS: eastern cooperative oncology group-performance status; NSCLC: non-small cell lung cancer